SPDR Dow Jones Industrial Average ETF

SPDR S&P 500 ETF Trust

Invesco QQQ Trust Series 1

Albemarle Corp. engages in the development, manufacture, and marketing of chemicals for consumer electronics, petroleum refining, utilities, packaging, construction, transportation, pharmaceuticals, crop production, food-safety, and custom chemistry services. It operates through the following segments: Energy Storage, Specialties, and Ketjen. The Energy Storage segment develops and manufactures a broad range of basic lithium compounds, including lithium carbonate, lithium hydroxide, and lithium chloride. The Specialties segment focuses on optimizing a portfolio of bromine and specialized lithium solutions. The Ketjen segment consists of clean fuels technologies, fluidized catalytic cracking catalysts and additives, and performance catalyst solutions, which is primarily composed of organometallics and curatives. The company was founded in 1993 and is headquartered in Charlotte, NC.

Albemarle Corp.

Albemarle Corp

Albemarle is drawing attention as traders link its continued weakness to falling lithium prices and futures, with upcoming earnings and guidance adding to uncertainty about when the downturn may bottom. Some see the selloff as a buying opportunity, citing longer-term lithium demand and supply constraints, while others expect more downside if prices keep falling.

TG Therapeutics, Inc. engages in the acquisition, development, and commercialization of novel treatments for B-cell malignancies and autoimmune diseases. Its product pipeline includes TG-1501, TG-1701, Ublituximab, and Umbralisib. The company was founded by Michael Sean Weiss and Laurence H. Shaw on May 18, 1993 and is headquartered in Morrisville, NC.

TG Therapeutics Inc

TGTX has climbed to a fresh 52-week high ahead of expected quarterly results, with traders pointing to BRIUMVIs sales growth and hoping for strong results. Buyout interest and short covering are also prominent theories for the rally, but no acquisition has been confirmed.

Okta, Inc. engages in the provision of an identity management platform for enterprises. The firm operates through the following geographical segments: United States and International. Its products include single sign-on, multi-factor authentication, access gateway, API access management, authentication, adaptive MFA and lifecycle management. The company was founded by Todd McKinnon and J. Frederic Kerrest in 2009 and is headquartered in San Francisco, CA.

Okta Inc - Ordinary Shares - Class A

Okta Inc

Oktas S&P 500 inclusion and repeated earnings beats are drawing attention, but traders are debating whether index-related demand can offset the stocks decline amid weakness across cybersecurity shares. Some attribute the pressure to claims of a DHS data breach involving Okta, though those claims are unverified in the discussion.

Microsoft Corp. engages in the development and support of software, services, devices, and solutions. It operates through the following segments: Productivity and Business Processes, Intelligent Cloud, and More Personal Computing. The Productivity and Business Processes segment is composed of products and services relating to productivity, communication, and information services such as Office Commercial, Office Consumer, LinkedIn, and Dynamics business solutions. The Intelligent Cloud segment consists of public, private, and hybrid server products and cloud services for businesses and developers, as well as enterprise and partner services. The More Personal Computing segment refers to products and services including Windows operating system, Windows cloud services, Surface, HoloLens, personal computer accessories, Xbox hardware, Xbox Cloud Gaming, Microsoft News, and Microsoft Edge. The company was founded by Paul Gardner Allen and William Henry Gates, III in 1975 and is headquartered in Redmond, WA.

Microsoft Corporation

Microsoft Corp

Microsofts earnings beat and accelerating Azure growth fueled optimism about AI demand, but the post-earnings gains faded as traders focused on heavy AI infrastructure spending and a new bond offering. The debate centers on whether cloud growth and cash generation will justify the investment, while some traders blame broader weakness in big tech for weighing on the shares.

CVS Health Corp. is a health solutions company, which engages in the provision of healthcare services. It operates through the following segments: Health Care Benefits, Health Services, Pharmacy and Consumer Wellness, and Corporate and Other. The Health Care Benefits segment operates as a health care benefits provider. The Health Services segment offers a full range of PBM solutions, delivers health care services in its medical clinics, virtually, and in the home. The Pharmacy & Consumer Wellness segment dispenses prescriptions in its retail pharmacies and through its infusion operations. The Corporate and Other Segment is involved in management and administrative expenses. The company was founded by Stanley P. Goldstein and Ralph Hoagland in 1963 and is headquartered in Woonsocket, RI.

CVS Health Corp

CVS is drawing attention over weaker Aetna Medicare Advantage star ratings for 2027, which traders say could reduce quality-bonus revenue and pressure margins. The outlook is debated, with some viewing the ratings decline as a headwind while others question whether the risk is already reflected in the shares.

FuboTV, Inc. is a consumer-first live TV streaming company with the mission of delivering premium sports, news and entertainment programming that offers greater choice, flexibility and value. The company was founded by David Gandler, Alberto Horihuela Suarez, and Sung Ho Choi on February 20, 2009 and is headquartered in New York, NY.

fuboTV Inc - Ordinary Shares - Class A

fuboTV Inc

Fubos steep, volatile decline and repeated lowsoften described by traders as happening without clear company-specific newsdominate the discussion, with attention focused on earnings and CEO Alisa Bowens strategic plan. Bearish traders cite business and dilution concerns, while bulls point to potential Disney/Hulu integration progress and speculate about a rebound or short covering.

CleanSpark, Inc. is a bitcoin mining technology company, which engages in the management of data centers. Its operations include College Park, Norcross, Washington, Sandersville, Dalton, and Massena. The company was founded by S. Matthew Schultz and Bryan Huber on October 15, 1987 and is headquartered in Henderson, NV.

Cleanspark Inc

A steep selloff in CleanSpark and other bitcoin-mining and data-center stocks is dominating discussion, with traders citing sector weakness, debt and interest-rate concerns, and CLSKs lagging performance despite comparatively resilient bitcoin prices. Bulls point to the Meta data-center lease and the companys bitcoin holdings, while bears remain focused on leverage, management, and continued downside.

Iovance Biotherapeutics, Inc. engages in the development and commercialization of cell therapies using autologous tumor-infiltrating lymphocytes (TIL) for the treatment of cancer. Its products include Amtagvi (lifileucel), and Proleukin (aldesleukin). The firm also develops investigational TIL therapies for other solid tumor cancers. The company was founded by Robert T. Brooke on September 17, 2007 and is headquartered in San Carlos, CA.

Iovance Biotherapeutics Inc

Updated NSCLC trial data and a shift toward biomarker-selected lung-cancer studies are driving attention, after the broader patient group showed a more modest response and durability remains immature, with a supplemental filing now planned for 2027. Traders are divided: some see the strong subgroup results as a promising precision-treatment strategy, while others focus on the narrower opportunity, longer timeline, and managements unclear presentation.

CorMedix, Inc. is a pharmaceutical and medical device company, which engages in the development and commercialization of therapeutic products for the prevention and treatment of diseases and conditions. The company was founded by Antony E. Pfaffle on July 28, 2006 and is headquartered in Berkeley Heights, NJ.

CorMedix Inc

CorMedix shares are under pressure after DaVita warned that Medicares add-on reimbursement for DefenCath could decline in 2027, raising concerns about the products pricing and revenue outlook. Traders are divided over whether DaVitas estimate is a reliable signal or preliminary speculation, with some viewing the selloff as an overreaction and criticizing managements lack of clarity.

Celcuity, Inc. operates as a cellular analysis company. The company discovers new cancer sub-types and commercializing diagnostic tests designed to improve the clinical outcomes of cancer patients treated with targeted therapies. The firm's proprietary CELx diagnostic platform is the commercially ready technology that uses a patient's living tumor cells to identify the specific abnormal cellular process driving a patient's cancer and the targeted therapy that treats it. The company was founded by Brian F. Sullivan and Lance G. Laing in January 2012 and is headquartered in Minneapolis, MN.

Celcuity Inc

Attention centers on updated Phase 3 VIKTORIA-1 data for gedatolisib in PIK3CA-mutant breast cancer, with traders highlighting the favorable progression-free-survival and response results and the pending FDA review of a label expansion. The community is split between optimism about the drugs clinical potential and concern that commercial uptake and revenue execution still need to validate the story.

statis crypto Watchlist

Bitcoin

Ethereum

Solana

Ripple

Dogecoin

Cardano

statis IN Watchlist

Nifty 50

Nifty Bank

Reliance Industries Ltd.

Zomato Ltd.

Tata Consultancy Services

Tata Motors Ltd.

HDFC Bank Ltd.

ITC Ltd.

Adani Enterprises Ltd

Axis Bank Ltd

Bajaj Finance Ltd

statis US Watchlist

SPDR S&P 500 ETF

Apple Inc.

Tesla Inc

NVIDIA Corp

 Hey, I want to invite you to join Stocktwits. It’s the largest global community of active traders. You’ll get access to the real-time market insights, news, discussion and much more! You can sign up using my unique link below 
 


 has invited you to join Stocktwits

$LIFX Q2 &#39;26 Earnings Results &amp; Recap

For FY 2026, Life360 expects consolidated revenue of $650 million to $685 million, and maintains its outlook for Adjusted EBITDA of $130 million to $140 million, representing a 20% margin.

Stocktwits

Life360 Inc

 Q2 '26 Earnings Results & Recap

For FY 2026, Life360 expects consolidated revenue of $650 million to $685 million, and maintains its outlook for Adjusted EBITDA of $130 million to $140 million, representing a 20% margin.

This account has been verified as an official STOCKTWITS representative.